These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 19520774

  • 1. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
    Nassar AE, King I, Paris BL, Haupt L, Ndikum-Moffor F, Campbell R, Usuki E, Skibbe J, Brobst D, Ogilvie BW, Parkinson A.
    Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
    [Abstract] [Full Text] [Related]

  • 2. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
    Robertson P, DeCory HH, Madan A, Parkinson A.
    Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
    [Abstract] [Full Text] [Related]

  • 3. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
    Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM.
    Toxicol Appl Pharmacol; 2004 Sep 15; 199(3):193-209. PubMed ID: 15364537
    [Abstract] [Full Text] [Related]

  • 4. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.
    Zhou D, Andersson TB, Grimm SW.
    Drug Metab Dispos; 2011 Apr 15; 39(4):703-10. PubMed ID: 21177984
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
    Guo Z, Raeissi S, White RB, Stevens JC.
    Drug Metab Dispos; 1997 Mar 15; 25(3):390-3. PubMed ID: 9172960
    [Abstract] [Full Text] [Related]

  • 8. Biotransformation and Rearrangement of Laromustine.
    Nassar AE, Wisnewski AV, King I.
    Drug Metab Dispos; 2016 Aug 15; 44(8):1349-63. PubMed ID: 27278961
    [Abstract] [Full Text] [Related]

  • 9. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
    Takusagawa S, Miyashita A, Iwatsubo T, Usui T.
    Xenobiotica; 2012 Dec 15; 42(12):1187-96. PubMed ID: 22834478
    [Abstract] [Full Text] [Related]

  • 10. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
    Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M.
    Clin Pharmacol Ther; 1996 Jun 15; 59(6):613-23. PubMed ID: 8681486
    [Abstract] [Full Text] [Related]

  • 11. Identification of the human P450 enzymes involved in lansoprazole metabolism.
    Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A.
    J Pharmacol Exp Ther; 1996 May 15; 277(2):805-16. PubMed ID: 8627562
    [Abstract] [Full Text] [Related]

  • 12. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
    Chang TK, Yu L, Maurel P, Waxman DJ.
    Cancer Res; 1997 May 15; 57(10):1946-54. PubMed ID: 9157990
    [Abstract] [Full Text] [Related]

  • 13. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
    Gan J, Liu-Kreyche P, Humphreys WG.
    Cancer Chemother Pharmacol; 2012 Jan 15; 69(1):51-6. PubMed ID: 21594721
    [Abstract] [Full Text] [Related]

  • 14. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
    Hong H, Su H, Ma L, Yao M, Iyer RA, Humphreys WG, Christopher LJ.
    Drug Metab Dispos; 2011 Sep 15; 39(9):1658-67. PubMed ID: 21673131
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028.
    Kim H, Yoon YJ, Kim H, Kang S, Cheon HG, Yoo SE, Shin JG, Liu KH.
    Toxicol Lett; 2006 Oct 10; 166(2):105-14. PubMed ID: 16857327
    [Abstract] [Full Text] [Related]

  • 16. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
    Ding Y, Jia Y, Lu C, Liu W, Yang J, Song Y, Zhu Y, Yang L, Ding L, Wen A.
    Biomed Pharmacother; 2012 Jun 10; 66(4):318-21. PubMed ID: 22397757
    [Abstract] [Full Text] [Related]

  • 17. Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).
    Nassar AE, King I, Du J.
    Chem Res Toxicol; 2011 Apr 18; 24(4):568-78. PubMed ID: 21361357
    [Abstract] [Full Text] [Related]

  • 18. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
    Arbus C, Benyamina A, Llorca PM, Baylé F, Bromet N, Massiere F, Garay RP, Hameg A.
    Eur J Pharm Sci; 2007 Dec 18; 32(4-5):357-66. PubMed ID: 17951033
    [Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
    Ventura V, Solà J, Peraire C, Brée F, Obach R.
    Drug Metab Dispos; 2012 Jul 18; 40(7):1268-78. PubMed ID: 22451700
    [Abstract] [Full Text] [Related]

  • 20. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
    Valles B, Schiller CD, Coassolo P, De Sousa G, Wyss R, Jaeck D, Viger-Chougnet A, Rahmani R.
    Drug Metab Dispos; 1995 Oct 18; 23(10):1051-7. PubMed ID: 8654192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.